nintedanib Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
angiogenesis inhibitors 4903 656247-17-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • BIBF1120
  • nibtedanib
  • nintedanib
  • nintedanib esylate
  • intedanib
  • BIBF 1120
  • ofev
  • nintedanib ethanesulfonate
  • vargatef
  • Molecular weight: 539.64
  • Formula: C31H33N5O4
  • CLOGP: 3.08
  • LIPINSKI: 1
  • HAC: 9
  • HDO: 2
  • TPSA: 94.22
  • ALOGS: -4.24
  • ROTB: 8

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 15 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 19.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 9.50 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
July 3, 2015 PMDA
Oct. 15, 2014 FDA BOEHRINGER INGELHEIM
Nov. 20, 2014 EMA Boehringer Ingelheim International GmbH

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diarrhoea 1320.26 53.82 404 976 83160 2273545
Nausea 664.41 53.82 265 1115 111924 2244781
Idiopathic pulmonary fibrosis 611.62 53.82 84 1296 188 2356517
Vomiting 470.68 53.82 184 1196 71418 2285287
Decreased appetite 356.41 53.82 119 1261 28772 2327933
Dyspnoea 231.79 53.82 116 1264 78617 2278088
Weight decreased 201.63 53.82 78 1302 28293 2328412
Fatigue 200.54 53.82 108 1272 84765 2271940
Constipation 180.72 53.82 67 1313 21562 2335143
Pneumonia 169.29 53.82 81 1299 49215 2307490
Stomatitis 146.99 53.82 47 1333 9663 2347042
Pulmonary embolism 136.21 53.82 52 1328 18031 2338674
Alanine aminotransferase increased 126.27 53.82 46 1334 13986 2342719
White blood cell count decreased 125.15 53.82 49 1331 18159 2338546
Aspartate aminotransferase increased 123.43 53.82 44 1336 12568 2344137
Malignant neoplasm progression 121.29 53.82 43 1337 12085 2344620
Liver disorder 113.44 53.82 35 1345 6379 2350326
Febrile neutropenia 110.36 53.82 39 1341 10843 2345862
Abdominal pain upper 109.30 53.82 47 1333 22053 2334652
General physical health deterioration 107.58 53.82 41 1339 14098 2342607
Anaemia 106.45 53.82 53 1327 34739 2321966
Abdominal pain 101.12 53.82 51 1329 34323 2322382
Hepatic enzyme increased 98.86 53.82 35 1345 9767 2346938
Gamma-glutamyltransferase increased 92.63 53.82 29 1351 5533 2351172
Neutrophil count decreased 87.89 53.82 29 1351 6538 2350167
Dizziness 83.08 53.82 54 1326 58611 2298094
Dehydration 80.19 53.82 38 1342 22257 2334448
Pyrexia 79.87 53.82 51 1329 53657 2303048
Cough 79.73 53.82 43 1337 33074 2323631
Asthenia 75.85 53.82 47 1333 46879 2309826
Alopecia 74.55 53.82 36 1344 21965 2334740
Liver function test increased 63.65 53.82 19 1361 3082 2353623
Acute kidney injury 63.42 53.82 35 1345 28087 2328618
Hypertension 61.55 53.82 34 1346 27327 2329378
Epistaxis 58.94 53.82 24 1356 9755 2346950
Cerebrovascular accident 56.41 53.82 29 1351 20157 2336548
Drug-induced liver injury 56.20 53.82 18 1362 3681 2353024
Urinary tract infection 56.03 53.82 33 1347 29909 2326796
Sepsis 55.85 53.82 28 1352 18460 2338245
Hepatic function abnormal 54.75 53.82 20 1360 6072 2350633

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Idiopathic pulmonary fibrosis 2482.36 50.40 375 2512 331 1743563
Diarrhoea 2117.52 50.40 706 2181 53146 1690748
Decreased appetite 549.87 50.40 216 2671 23655 1720239
Dyspnoea 465.36 50.40 243 2644 51816 1692078
Nausea 437.39 50.40 232 2655 50964 1692930
Weight decreased 423.49 50.40 177 2710 22576 1721318
Pneumonia 334.18 50.40 188 2699 45994 1697900
Malignant neoplasm progression 278.76 50.40 115 2772 14043 1729851
Pneumothorax 253.04 50.40 71 2816 2641 1741253
Fatigue 226.15 50.40 152 2735 50629 1693265
Respiratory failure 216.67 50.40 97 2790 14408 1729486
Death 210.43 50.40 181 2706 87262 1656632
Cough 190.75 50.40 97 2790 19100 1724794
Vomiting 180.48 50.40 119 2768 38196 1705698
Pulmonary embolism 178.02 50.40 82 2805 12977 1730917
Liver disorder 164.32 50.40 61 2826 5575 1738319
Lung transplant 147.42 50.40 32 2855 393 1743501
Asthenia 144.65 50.40 100 2787 34570 1709324
Constipation 143.58 50.40 74 2813 14926 1728968
Productive cough 139.10 50.40 48 2839 3543 1740351
Abdominal pain upper 124.99 50.40 61 2826 10940 1732954
Febrile neutropenia 124.47 50.40 61 2826 11039 1732855
Hepatic function abnormal 113.96 50.40 50 2837 7024 1736870
General physical health deterioration 112.01 50.40 60 2827 13058 1730836
Pyrexia 106.43 50.40 94 2793 46306 1697588
Dehydration 103.05 50.40 63 2824 17595 1726299
Epistaxis 100.14 50.40 48 2839 8258 1735636
Abdominal pain 98.91 50.40 66 2821 21424 1722470
Abnormal loss of weight 98.47 50.40 24 2863 504 1743390
Cardiac failure 97.45 50.40 54 2833 12548 1731346
Stomatitis 92.88 50.40 40 2847 5364 1738530
Abdominal discomfort 84.42 50.40 44 2843 9037 1734857
Dysgeusia 82.27 50.40 36 2851 5013 1738881
Neutropenic sepsis 77.89 50.40 25 2862 1467 1742427
White blood cell count decreased 76.84 50.40 47 2840 13102 1730792
Therapeutic product effect incomplete 76.48 50.40 35 2852 5413 1738481
Neutropenia 74.26 50.40 52 2835 18208 1725686
Neutrophil count decreased 72.81 50.40 35 2852 6046 1737848
Drug-induced liver injury 72.64 50.40 29 2858 3208 1740686
Pulmonary fibrosis 72.48 50.40 27 2860 2477 1741417
Pneumonia bacterial 70.59 50.40 22 2865 1172 1742722
Haemoptysis 64.29 50.40 30 2857 4846 1739048
Chest pain 63.54 50.40 49 2838 19865 1724029
Lung neoplasm malignant 62.82 50.40 26 2861 3153 1740741
Sepsis 62.39 50.40 48 2839 19390 1724504
Hypoxia 61.48 50.40 31 2856 5932 1737962
Pulmonary hypertension 59.55 50.40 24 2863 2718 1741176
Interstitial lung disease 57.48 50.40 35 2852 9661 1734233
Oxygen saturation decreased 57.03 50.40 29 2858 5646 1738248
Anaemia 56.23 50.40 54 2833 29403 1714491
Malaise 56.06 50.40 54 2833 29511 1714383
Hepatic enzyme increased 55.60 50.40 30 2857 6591 1737303
Flatulence 54.62 50.40 23 2864 2911 1740983
Faeces soft 54.54 50.40 14 2873 365 1743529
Haematochezia 51.88 50.40 26 2861 4906 1738988
Rectal haemorrhage 51.87 50.40 27 2860 5515 1738379
Deep vein thrombosis 51.71 50.40 33 2854 9887 1734007
Dizziness 51.01 50.40 55 2832 34306 1709588

Pharmacologic Action:

SourceCodeDescription
ATC L01XE31 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Protein kinase inhibitors
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:48422 angiogenesis inhibitor
FDA EPC N0000175605 Kinase Inhibitor
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D047428 Protein Kinase Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Non-small cell lung cancer indication 254637007 DOID:3908
Hamman-Rich syndrome indication 700250006 DOID:0050156

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.97 acidic
pKa2 7.77 Basic
pKa3 3.25 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 100MG BASE OFEV BOEHRINGER INGELHEIM N205832 Oct. 15, 2014 RX CAPSULE ORAL 10154990 Dec. 20, 2025 USE OF NINTEDANIB FOR SLOWING THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)
EQ 150MG BASE OFEV BOEHRINGER INGELHEIM N205832 Oct. 15, 2014 RX CAPSULE ORAL 10154990 Dec. 20, 2025 USE OF NINTEDANIB FOR SLOWING THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 100MG BASE OFEV BOEHRINGER INGELHEIM N205832 Oct. 15, 2014 RX CAPSULE ORAL Oct. 15, 2021 TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
EQ 150MG BASE OFEV BOEHRINGER INGELHEIM N205832 Oct. 15, 2014 RX CAPSULE ORAL Oct. 15, 2021 TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
EQ 100MG BASE OFEV BOEHRINGER INGELHEIM N205832 Oct. 15, 2014 RX CAPSULE ORAL Sept. 6, 2022 SLOW THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE
EQ 150MG BASE OFEV BOEHRINGER INGELHEIM N205832 Oct. 15, 2014 RX CAPSULE ORAL Sept. 6, 2022 SLOW THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE
EQ 100MG BASE OFEV BOEHRINGER INGELHEIM N205832 Oct. 15, 2014 RX CAPSULE ORAL March 9, 2023 TREATMENT FOR CHRONIC FIBROSING INTERSTITIAL LUNG DISEASES WITH A PROGRESSIVE PHENOTYPE
EQ 150MG BASE OFEV BOEHRINGER INGELHEIM N205832 Oct. 15, 2014 RX CAPSULE ORAL March 9, 2023 TREATMENT FOR CHRONIC FIBROSING INTERSTITIAL LUNG DISEASES WITH A PROGRESSIVE PHENOTYPE
EQ 100MG BASE OFEV BOEHRINGER INGELHEIM N205832 Oct. 15, 2014 RX CAPSULE ORAL Sept. 6, 2026 INDICATED TO SLOW THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)
EQ 150MG BASE OFEV BOEHRINGER INGELHEIM N205832 Oct. 15, 2014 RX CAPSULE ORAL Sept. 6, 2026 INDICATED TO SLOW THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Platelet-derived growth factor receptor beta Kinase INHIBITOR Kd 7.82 CHEMBL CHEMBL
Fibroblast growth factor receptor 2 Kinase INHIBITOR Kd 6.46 CHEMBL CHEMBL
Fibroblast growth factor receptor 1 Kinase INHIBITOR IC50 7.42 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Platelet-derived growth factor receptor alpha Kinase INHIBITOR IC50 7.74 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Fibroblast growth factor receptor 4 Kinase INHIBITOR Kd 5.74 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 1 Kinase INHIBITOR IC50 6.98 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Fibroblast growth factor receptor 3 Kinase INHIBITOR Kd 7.03 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 3 Kinase INHIBITOR IC50 8.30 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Vascular endothelial growth factor receptor 2 Kinase INHIBITOR IC50 8.30 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Tyrosine-protein kinase BTK Kinase Kd 6.51 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase Kd 6.24 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1 Kinase Kd 5.23 CHEMBL
Serine/threonine-protein kinase 35 Kinase Kd 6.09 CHEMBL
Calcium/calmodulin-dependent protein kinase type IV Kinase Kd 5.43 CHEMBL
Insulin receptor Kinase AGONIST Kd 7.62 CHEMBL
SRSF protein kinase 1 Kinase Kd 7.43 CHEMBL
Serine/threonine-protein kinase RIO3 Kinase Kd 7.44 CHEMBL
Hepatocyte growth factor receptor Kinase Kd 6.70 CHEMBL
Casein kinase I isoform epsilon Kinase Kd 6.64 CHEMBL
Myosin-IIIb Kinase Kd 5.57 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 3 Kinase Kd 5.68 CHEMBL
Serine/threonine-protein kinase PAK 3 Kinase Kd 6.68 CHEMBL
Ephrin type-B receptor 4 Kinase Kd 5.96 CHEMBL
Tyrosine-protein kinase JAK2 Kinase Kd 7.85 CHEMBL
Ribosomal protein S6 kinase alpha-6 Kinase Kd 6.64 CHEMBL
MAP/microtubule affinity-regulating kinase 3 Kinase Kd 6.11 CHEMBL
Ribosomal protein S6 kinase alpha-1 Kinase Kd 6.74 CHEMBL
Serine/threonine-protein kinase SBK1 Kinase Kd 6.96 CHEMBL
Mitogen-activated protein kinase kinase kinase 15 Kinase Kd 5.85 CHEMBL
Microtubule-associated serine/threonine-protein kinase 1 Kinase Kd 5.34 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5 Kinase Kd 8.74 CHEMBL
Tyrosine-protein kinase JAK1 Kinase Kd 8.32 CHEMBL
Casein kinase I isoform delta Kinase Kd 5.89 CHEMBL
Tyrosine-protein kinase ITK/TSK Kinase Kd 6.68 CHEMBL
Homeodomain-interacting protein kinase 3 Kinase Kd 6.07 CHEMBL
Homeodomain-interacting protein kinase 2 Kinase Kd 6.10 CHEMBL
Maternal embryonic leucine zipper kinase Kinase Kd 8.31 CHEMBL
Wee1-like protein kinase Kinase Kd 5.54 CHEMBL
NUAK family SNF1-like kinase 1 Kinase Kd 6.80 CHEMBL
Serine/threonine-protein kinase D1 Kinase Kd 6 CHEMBL
Mitogen-activated protein kinase kinase kinase 13 Kinase Kd 6.85 CHEMBL
Serine/threonine-protein kinase TBK1 Kinase Kd 6.82 CHEMBL
Serine/threonine-protein kinase ICK Kinase Kd 5.77 CHEMBL
Ephrin type-A receptor 1 Kinase Kd 5.92 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1 Kinase Kd 7.46 CHEMBL
Serine/threonine-protein kinase/endoribonuclease IRE1 Kinase Kd 5.70 CHEMBL
MAP/microtubule affinity-regulating kinase 4 Kinase Kd 5.70 CHEMBL
Tyrosine-protein kinase Fgr Kinase Kd 6.52 CHEMBL
Serine/threonine-protein kinase OSR1 Kinase Kd 5.89 CHEMBL
Serine/threonine-protein kinase D3 Kinase Kd 6.19 CHEMBL
Serine/threonine-protein kinase Sgk3 Kinase Kd 6 CHEMBL
STE20/SPS1-related proline-alanine-rich protein kinase Kinase Kd 6.28 CHEMBL
Mitogen-activated protein kinase kinase kinase 7 Kinase Kd 8.39 CHEMBL
Dual specificity protein kinase CLK2 Kinase Kd 6.12 CHEMBL
G protein-coupled receptor kinase 7 Kinase Kd 5.92 CHEMBL
Tyrosine-protein kinase FRK Kinase Kd 5.57 CHEMBL
Myosin light chain kinase family member 4 Kinase Kd 6.36 CHEMBL
Homeodomain-interacting protein kinase 1 Kinase Kd 5.89 CHEMBL
Dual specificity protein kinase CLK1 Kinase Kd 8.06 CHEMBL
Dual specificity protein kinase TTK Kinase Kd 7.66 CHEMBL
Ephrin type-A receptor 2 Kinase Kd 5.54 CHEMBL
Ephrin type-A receptor 3 Kinase Kd 5.07 CHEMBL
Serine/threonine-protein kinase 10 Kinase Kd 7.06 CHEMBL
Tyrosine-protein kinase Fer Kinase Kd 7.14 CHEMBL
Serine/threonine-protein kinase 16 Kinase Kd 7.74 CHEMBL
Serine/threonine-protein kinase 17B Kinase Kd 6.17 CHEMBL
Serine/threonine-protein kinase PLK4 Kinase Kd 7.28 CHEMBL
AP2-associated protein kinase 1 Kinase Kd 7.20 CHEMBL
Serine/threonine-protein kinase MARK2 Kinase Kd 5.85 CHEMBL
Tyrosine-protein kinase JAK3 Kinase Kd 8.09 CHEMBL
Ribosomal protein S6 kinase alpha-5 Kinase Kd 6.70 CHEMBL
Casein kinase II subunit alpha' Kinase Kd 6.05 CHEMBL
Tyrosine-protein kinase Yes Kinase Kd 7.10 CHEMBL
Serine/threonine-protein kinase N2 Kinase Kd 5.85 CHEMBL
Tyrosine-protein kinase HCK Kinase Kd 5.28 CHEMBL
Aurora kinase C Kinase Kd 6.72 CHEMBL
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Kinase Kd 6.59 CHEMBL
High affinity nerve growth factor receptor Kinase Kd 8.35 CHEMBL
Ribosomal protein S6 kinase alpha-3 Kinase Kd 7.19 CHEMBL
Homeodomain-interacting protein kinase 4 Kinase Kd 5.92 CHEMBL
Myosin light chain kinase, smooth muscle Kinase Kd 6.54 CHEMBL
Mitogen-activated protein kinase kinase kinase 10 Kinase Kd 5.64 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5 Kinase Kd 6.41 CHEMBL
Misshapen-like kinase 1 Kinase Kd 7.09 CHEMBL
Leucine-rich repeat serine/threonine-protein kinase 2 Kinase Kd 7.43 CHEMBL
Interleukin-1 receptor-associated kinase 4 Kinase Kd 6.09 CHEMBL
Insulin receptor-related protein Kinase Kd 7.68 CHEMBL
Mast/stem cell growth factor receptor Kit Kinase Kd 8.57 CHEMBL
BMP-2-inducible protein kinase Kinase Kd 8.66 CHEMBL
Serine/threonine-protein kinase PAK 7 Kinase Kd 5.89 CHEMBL
Serine/threonine-protein kinase 17A Kinase Kd 6.96 CHEMBL
Mitogen-activated protein kinase kinase kinase 11 Kinase Kd 6.15 CHEMBL
Insulin-like growth factor 1 receptor Kinase Kd 7.21 CHEMBL
Ephrin type-A receptor 6 Kinase Kd 6.03 CHEMBL
TRAF2 and NCK-interacting protein kinase Kinase Kd 7.28 CHEMBL
Calcium/calmodulin-dependent protein kinase kinase 2 Kinase Kd 6.04 CHEMBL
Ribosomal protein S6 kinase alpha-4 Kinase Kd 6.21 CHEMBL
Aurora kinase B Kinase Kd 6.38 CHEMBL
STE20-like serine/threonine-protein kinase Kinase Kd 7.29 CHEMBL
Dual specificity protein kinase CLK4 Kinase Kd 7.74 CHEMBL
Death-associated protein kinase 2 Kinase Kd 5.49 CHEMBL
Non-receptor tyrosine-protein kinase TYK2 Kinase Kd 7.43 CHEMBL
Interleukin-1 receptor-associated kinase 1 Kinase Kd 6.92 CHEMBL
Serine/threonine-protein kinase 4 Kinase Kd 8.05 CHEMBL
Calcium/calmodulin-dependent protein kinase kinase 1 Kinase Kd 6.20 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1D Kinase Kd 5.66 CHEMBL
Serine/threonine-protein kinase 3 Kinase Kd 7.42 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1G Kinase Kd 6.59 CHEMBL
5'-AMP-activated protein kinase catalytic subunit alpha-1 Kinase Kd 7.06 CHEMBL
Tyrosine-protein kinase Lyn Kinase Kd 6.03 CHEMBL
Ribosomal protein S6 kinase alpha-2 Kinase Kd 7.24 CHEMBL
Serine/threonine-protein kinase ULK2 Kinase Kd 6.42 CHEMBL
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform Kinase Kd 6.85 CHEMBL
Ephrin type-B receptor 1 Kinase Kd 6.26 CHEMBL
Activated CDC42 kinase 1 Kinase Kd 5.80 CHEMBL
Cyclin-dependent kinase 16 Kinase Kd 7.68 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 3 Kinase Kd 6.54 CHEMBL
Focal adhesion kinase 1 Kinase Kd 6.68 CHEMBL
Casein kinase II subunit alpha Kinase Kd 5.12 CHEMBL
NT-3 growth factor receptor Kinase Kd 7.49 CHEMBL
Serine/threonine-protein kinase STK11 Kinase Kd 7.74 CHEMBL
Rhodopsin kinase Kinase Kd 6 CHEMBL
Tyrosine-protein kinase ZAP-70 Kinase Kd 5.46 CHEMBL
Activin receptor type-1 Kinase Kd 6.22 CHEMBL
Interleukin-1 receptor-associated kinase 3 Kinase Kd 5.28 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit alpha Kinase Kd 5.44 CHEMBL
G protein-coupled receptor kinase 4 Kinase Kd 7.77 CHEMBL
Mitogen-activated protein kinase kinase kinase 2 Kinase Kd 8.03 CHEMBL
Cyclin-dependent kinase 2 Kinase Kd 5.85 CHEMBL
Serine/threonine-protein kinase ULK3 Kinase Kd 7.22 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 5.70 CHEMBL
Serine/threonine-protein kinase MARK1 Kinase Kd 5.85 CHEMBL
Serine/threonine-protein kinase 26 Kinase Kd 7.31 CHEMBL
Bone morphogenetic protein receptor type-2 Kinase Kd 7.25 CHEMBL
Protein-tyrosine kinase 2-beta Kinase Kd 7.09 CHEMBL
Tyrosine-protein kinase Blk Kinase Kd 6.42 CHEMBL
Serine/threonine-protein kinase LATS2 Kinase Kd 6.42 CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit alpha Kinase Kd 5.35 CHEMBL
Angiopoietin-1 receptor Kinase Kd 5.85 CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit epsilon Kinase Kd 6.77 CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 1B Kinase Kd 5.80 CHEMBL
Serine/threonine-protein kinase PRP4 homolog Kinase Kd 8.08 CHEMBL
Proto-oncogene tyrosine-protein kinase ROS Kinase Kd 5.43 CHEMBL
Ephrin type-B receptor 6 Kinase Kd 6.85 CHEMBL
Mitogen-activated protein kinase 8 Kinase Kd 6.20 CHEMBL
Serine/threonine-protein kinase SIK2 Kinase Kd 6.55 CHEMBL
Cyclin-dependent kinase 7 Kinase Kd 6.52 CHEMBL
Serine/threonine-protein kinase 24 Kinase Kd 6.96 CHEMBL
5'-AMP-activated protein kinase catalytic subunit alpha-2 Kinase Kd 7.08 CHEMBL
Tyrosine-protein kinase Fyn Kinase Kd 6.20 CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase Kd 7.32 CHEMBL
Uncharacterized serine/threonine-protein kinase SBK3 Kinase Kd 5.70 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 7.38 CHEMBL
Cyclin-dependent kinase 17 Kinase Kd 7.03 CHEMBL
Death-associated protein kinase 3 Kinase Kd 5.68 CHEMBL
Serine/threonine-protein kinase receptor R3 Kinase Kd 5.38 CHEMBL
Activin receptor type-1B Kinase Kd 5.31 CHEMBL
Tyrosine-protein kinase receptor Tie-1 Kinase Kd 5.66 CHEMBL
TGF-beta receptor type-1 Kinase Kd 5.38 CHEMBL
Serine/threonine-protein kinase PAK 4 Kinase Kd 5.52 CHEMBL
Serine/threonine-protein kinase DCLK3 Kinase Kd 6.11 CHEMBL
Cyclin-dependent kinase 14 Kinase Kd 6.33 CHEMBL
Eukaryotic translation initiation factor 2-alpha kinase 4 Kinase Kd 5.70 CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase Kd 8.02 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 7.92 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 4 Kinase Kd 6.82 CHEMBL
Cyclin-dependent kinase 18 Kinase Kd 6.29 CHEMBL
Serine/threonine-protein kinase LATS1 Kinase Kd 6.38 CHEMBL
Serine/threonine-protein kinase PAK 2 Kinase Kd 5.48 CHEMBL
Tyrosine-protein kinase receptor TYRO3 Kinase Kd 5.31 CHEMBL
Tyrosine-protein kinase Fes/Fps Kinase Kd 5.92 CHEMBL
Tyrosine-protein kinase Lck Kinase Kd 8.21 CHEMBL
Myosin light chain kinase 2, skeletal/cardiac muscle Kinase Kd 5.40 CHEMBL
Mitogen-activated protein kinase kinase kinase 9 Kinase Kd 6.66 CHEMBL
Leukocyte tyrosine kinase receptor Kinase Kd 6.82 CHEMBL
Mitogen-activated protein kinase kinase kinase 19 Kinase Kd 8.28 CHEMBL
Tyrosine-protein kinase receptor UFO Kinase Kd 7.92 CHEMBL
Phosphatidylinositol 5-phosphate 4-kinase type-2 beta Kinase Kd 7.77 CHEMBL
3-phosphoinositide-dependent protein kinase 1 Kinase Kd 5.55 CHEMBL
Serine/threonine-protein kinase D2 Kinase Kd 6.14 CHEMBL
BDNF/NT-3 growth factors receptor Kinase Kd 7.72 CHEMBL
NUAK family SNF1-like kinase 2 Kinase Kd 7.68 CHEMBL
SRSF protein kinase 2 Kinase Kd 7.44 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 2 Kinase Kd 7.38 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 4 Kinase Kd 5.43 CHEMBL
SRSF protein kinase 3 Kinase Kd 7.92 CHEMBL
Tyrosine-protein kinase TXK Kinase Kd 6.07 CHEMBL
ALK tyrosine kinase receptor Kinase Kd 7.51 CHEMBL
Mitogen-activated protein kinase kinase kinase 12 Kinase Kd 6.85 CHEMBL
Myosin light chain kinase 3 Kinase Kd 6.96 CHEMBL
Receptor-interacting serine/threonine-protein kinase 1 Kinase Kd 6.62 CHEMBL
Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha Kinase Kd 7.31 CHEMBL
Mitogen-activated protein kinase kinase kinase 3 Kinase Kd 7.47 CHEMBL
Serine/threonine-protein kinase RIO1 Kinase Kd 7.64 CHEMBL
Cyclin-dependent kinase 4 Kinase Kd 6.80 CHEMBL
Ribosomal protein S6 kinase beta-1 Kinase Kd 6.72 CHEMBL
Serine/threonine-protein kinase ULK1 Kinase Kd 6.47 CHEMBL
Serine/threonine-protein kinase 33 Kinase Kd 5.96 CHEMBL
Testis-specific serine/threonine-protein kinase 1 Kinase Kd 5.21 CHEMBL
Glycogen synthase kinase-3 beta Kinase Kd 7.08 CHEMBL
Serine/threonine-protein kinase Chk1 Kinase Kd 6.54 CHEMBL
Glycogen synthase kinase-3 alpha Kinase Kd 6.37 CHEMBL
cGMP-dependent protein kinase 1 Kinase Kd 7.85 CHEMBL
Receptor-interacting serine/threonine-protein kinase 4 Kinase Kd 6.36 CHEMBL
Serine/threonine-protein kinase N1 Kinase Kd 6.13 CHEMBL
Serine/threonine-protein kinase SIK1 Kinase Kd 6.17 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 2 Kinase Kd 6.54 CHEMBL
Tyrosine-protein kinase Mer Kinase Kd 8.07 CHEMBL
Mitogen-activated protein kinase 7 Kinase Kd 5.60 CHEMBL
Non-receptor tyrosine-protein kinase TNK1 Kinase Kd 6.68 CHEMBL
Mitogen-activated protein kinase 10 Kinase Kd 6.57 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 1 Kinase Kd 8 CHEMBL
Tyrosine-protein kinase ABL1 Kinase Kd 8 CHEMBL
Cyclin-dependent kinase-like 2 Kinase Kd 5.89 CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase Kd 9.38 CHEMBL
Protein kinase C theta type Kinase Kd 5.26 CHEMBL
Serine/threonine-protein kinase DCLK1 Kinase Kd 6.27 CHEMBL
Muscle, skeletal receptor tyrosine-protein kinase Kinase Kd 6.23 CHEMBL
Serine/threonine-protein kinase PknB Kinase Kd 8.44 CHEMBL
Calcium-dependent protein kinase 1 Kinase Kd 5.92 CHEMBL
Vascular endothelial growth factor receptor 2 Kinase IC50 7.89 CHEMBL

External reference:

IDSource
D10396 KEGG_DRUG
4033814 VUID
N0000191096 NUI
C2930789 UMLSCUI
42F62RTZ4G UNII
656247-18-6 SECONDARY_CAS_RN
715613009 SNOMEDCT_US
1592737 RXNORM
015720 NDDF
4033814 VANDF
30617 MMSL
d08301 MMSL
712494002 SNOMEDCT_US
135423438 PUBCHEM_CID
CHEBI:85164 CHEBI
CHEMBL502835 ChEMBL_ID
9229 INN_ID
DB09079 DRUGBANK_ID
CHEMBL3039504 ChEMBL_ID
5936 IUPHAR_LIGAND_ID
C530716 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ofev HUMAN PRESCRIPTION DRUG LABEL 1 0597-0143 CAPSULE 100 mg ORAL NDA 19 sections
Ofev HUMAN PRESCRIPTION DRUG LABEL 1 0597-0145 CAPSULE 150 mg ORAL NDA 19 sections